Pediatric Drugs

, Volume 16, Issue 4, pp 267–274

The Pharmacologic Management of Delirium in Children and Adolescents

Review Article

Abstract

Delirium is a serious and common problem in severely medically ill patients of all ages. It has been less addressed in children and adolescents. Treatment of delirium is predicated on addressing its underlying cause. The management of its symptoms depends on the off-label use of antipsychotics, while avoiding agents that precipitate or worsen delirium. Olanzapine, quetiapine, and risperidone are presently considered first-line drugs, usually replacing haloperidol. Other agents have shown promise, including melatonin to address the sleep disturbance characteristic of delirium, and dexmedetomidine, an α2-agonist, that may facilitate lower doses of benzodiazepines and opioids that may worsen delirium.

References

  1. 1.
    Engel GL, Romano J. Delirium, a syndrome of cerebral insufficiency. J Chronic Dis. 1959;9:260–77.PubMedCrossRefGoogle Scholar
  2. 2.
    Romano J, Engel GL. Delirium I. Electroencephalographic data. Arch Neurol Psychiatr. 1944;51:356–77.CrossRefGoogle Scholar
  3. 3.
    Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, Corbera K, Raymond S, Lund S, Jacobsen P. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatr. 1996;153:231–7.PubMedGoogle Scholar
  4. 4.
    Trzepacz PT, Breitbart W, Levenson J, Franklin J, Martini DR. Practice guideline for the treatment of patients with delirium. Am J Psychiatr. 1999;156(5):1–20.Google Scholar
  5. 5.
    Harrison AM, Lugo RA, Lee EW, Appachi E, Bourdakos D, Davis SJ, McHugh MJ, Weise KL. The use of haloperidol in agitated critically ill children. Clin Pediatr. 2002;41:51–4.CrossRefGoogle Scholar
  6. 6.
    Deksnytė A, Aranauskas R, Budrys V, Kasieulevicė V, Ŝapoka V. Delirium: its historical evolution and current interpretation. Eur J Int Med. 2012;23:483–6.CrossRefGoogle Scholar
  7. 7.
    Smeets IAP, Tan EYL, Vossen HGM, Leroy PLJM, Lousberg RHB, van Os J, Schieveld JNM. Prolonged stay at the pediatric intensive care unit associated with pediatric delirium. Eur Child Adolesc Psychiatr. 2010;19:389–93.CrossRefGoogle Scholar
  8. 8.
    Eisendrath SJ, Shim JJ. Management of psychiatric problems in critically ill patients. Am J Med. 2006;119:22–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Lacasse H, Perreault MM, Williamson DR. Systemic review of antipsychotics for the treatment of hospital associated delirium in medically and surgically ill patients. Ann Pharmacother. 2006;40:1966–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Prugh DC, Wagonfield S, Metcalf D, Jordan K. A clinical study of delirium in children and adolescents. Psychosom Med. 1980;42 suppl:177–95.CrossRefGoogle Scholar
  11. 11.
    Girard TD, Jackson JC, Pandharipande PP, Thompson JL, Shintani AK, Ely EW. Duration of delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Am J Respir Crit Care Med. 2009;179:A5477.Google Scholar
  12. 12.
    Hatherill S, Flisher AJ. Delirium in children and adolescents: a systematic review of the literature. J Psychosom Res. 2010;68:337–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Rummans TA, Evans JM, Krahn LE, Fleming KC. Delirium in elderly patients: evaluation and management. Mayo Clin Proc. 1995;70:989–98.PubMedCrossRefGoogle Scholar
  14. 14.
    de Rooij SE, van Munster BC, Korevaar JC, Levi M. Cytokines and acute phase response in delirium. J Psychosom Res. 2007;62:521–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Maldonado JR. Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment. Crit Care Clin. 2008;24:789–856.PubMedCrossRefGoogle Scholar
  16. 16.
    Rudolph JL, Ramlawi B, Kuchel GA, McElhaney JE, Xie D, Sellke FW, Khabbaz K, Levkoff SE, Marcantonio ER. Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Med Sci. 2008;63:184–9.Google Scholar
  17. 17.
    Silver GH, Kearney JA, Kutko MC, Bartell AS. Infant delirium in pediatric critical care settings. Am J Psychiatr. 2010;167:1172–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Tune L, Egeli S. Acetylcholine and delirium. Dement Geriatr Cogn Disord. 1999;10:342–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Cerejeira J, Nogueira V, Luis P, Vaz-Serra A, Mukaetova-Ladinska EB. The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc. 2012;60:669–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Eikelenboom P, Hoogendijk WJG, Jonker C, van Tilburg W. Immunologic mechanisms and the spectrum of psychiatric syndromes in Alzheimer’s disease. J Psychiatr Res. 2002;36:269–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Seaman JS, Schillerstrom J, Carroll D, Brown TM. Impaired oxidative metabolism precipitates delirium: a study of 101 ICU patients. Psychosomatics. 2006;47:56–61.PubMedCrossRefGoogle Scholar
  22. 22.
    MacLullich AMJ, Ferguson KJ, Miller T, de Rooij SEJA, Cunningham C. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress response. J Psychosom Res. 2008;65:229–38.PubMedCrossRefGoogle Scholar
  23. 23.
    Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatr. 1992;149:1393–4.PubMedGoogle Scholar
  24. 24.
    Brummel NE, Girard TD. Preventing delirium in the intensive care unit. Crit Care Clin. 2013;29:51–65.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Aging. 2011;40:23–9.CrossRefGoogle Scholar
  26. 26.
    Stoddard FJ, Usher CT, Abrams AN. Psychopharmacology in pediatric critical care. Child Adolesc Clin North Am. 2006;15:611–55.CrossRefGoogle Scholar
  27. 27.
    Kollef MH, Levy NT, Ahrens TS, Schaiff R, Prentice D, Sherman G. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. Chest. 1998;114:541–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med. 2000;28:2122–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Schieveld JN, Staal M, Voogd L, Fioncken J, Vos G, van Os J. Refractory agitation as a marker for pediatric delirium in very young infants in the intensive care unit. Intensive Care Med. 2010;36:1982–3.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Kean J, Trzepacz PT, Murray LL, Abell M, Trexler L. Initial validation of a brief provisional diagnostic scale for delirium. Brain Injury. 2010;24:1222–30.PubMedCrossRefGoogle Scholar
  31. 31.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, revised (DSM-TR-IV). Washington, DC: American Psychiatric Press; 2000.CrossRefGoogle Scholar
  32. 32.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Washington, DC: American Psychiatric Press; 2013.Google Scholar
  33. 33.
    Turkel SB, Trzepacz PT, Tavare CJ. Comparing symptoms of delirium in adults and children. Psychosomatics. 2006;47:320–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Grover S, Kate N, Malhotra S, Chakrabarti S, Mattoo SK, Avasthi A. Symptom profile of delirium in children and adolescent—does it differ from adults and elderly? Gen Hosp Psychiatr. 2012;34:626–32.CrossRefGoogle Scholar
  35. 35.
    Leentjens AFG, Schieveld JNM, Leonard M, Lousberg R, Verhey FRJ, Meagher DJ. A comparison of the phenomenology of pediatric, adult, and geriatric delirium. J Psychosom Res. 2008;64:219–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Turkel SB, Tavare CJ. Delirium in children and adolescents. J Neuropsychiatr Clin Neurosci. 2003;15:431–5.CrossRefGoogle Scholar
  37. 37.
    Turkel SB, Jacobson J, Tavaré CJ. The diagnosis and management of delirium in infancy. J Child Adolesc Psychopharmacol. 2013;25:352–6.CrossRefGoogle Scholar
  38. 38.
    Holditch-Davis D, Scher M, Schwartz T, Hudson-Barr D. Sleeping and waking state development in preterm infants. Early Hum Dev. 2004;80:43–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Meagher DJ, O’Hanlon D, O’Mahoney E, Casey PR, Trzepacz PT. Relationship between symptoms and motoric subtype of delirium.Google Scholar
  40. 40.
    Hart RP, Levenson JL, Sessler CN, Best AM, Schwartz SM, Rutherford LE. Validation of a cognitive test for delirium in medical intensive care patients. Psychosomatics. 1996;37:533–46.PubMedCrossRefGoogle Scholar
  41. 41.
    Grover S, Ghosh A, Kate N, Malhotra S, Mattoo SK, Chakrabarti S, Avasthi A. Do motor subtypes of delirium in child and adolescent have a different clinical and phenomenologic profile? Gen Hosp Psychiatry. 2014;36:187–91.PubMedCrossRefGoogle Scholar
  42. 42.
    van der Mast RC. Pathophysiology of delirium. J Geriatr Psychiatr Neurol. 1998;11:138–45.CrossRefGoogle Scholar
  43. 43.
    Grace JB, Holmes J. The management of behavioural and psychiatric symptoms in delirium. Expert Opin Pharmacother. 2006;7:555–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Meagher DJ, O’Hanlon D, O’Mahony E, Casey PR. The use of environmental strategies and psychotropic medication in the management of delirium. Br J Psychiatry. 1996;168:512–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Martini DR. Commentary: the diagnosis of delirium in pediatric patients. J Am Acad Child Adolesc Psychiatry. 2005;44:395–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Schieveld JN, Leeroy PL, van Os J, Nicolai J, Vos GD, Leentjens AP. Pediatric delirium in critical illness: phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit. Intensive Care Med. 2009;33:1033–40.CrossRefGoogle Scholar
  47. 47.
    Bourne RS, Tahir TA, Borthwick M, Sampson EL. Drug treatment of delirium: past, present and future. J Psychosom Res. 2008;65:273–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Devlin JW, Al-Qadhee NS, Skrobik Y. Pharmacologic prevention and treatment of delirium in critically ill and non-critically ill hospitalized patients: a review of data from prospective, randomized studies. Best Pract Res Clin Anaesthesiol. 2012;26:289–309.PubMedCrossRefGoogle Scholar
  49. 49.
    Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis, and treatment. Crit Care Clin. 2008;24:657–722.PubMedCrossRefGoogle Scholar
  50. 50.
    DeMaso DR, Martini DR, Cahen LA, Bukstein O, Walter HJ, Benson S, Chrisman A, Farchione T, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J, Work Group on Quality Issues. Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:213–33.PubMedCrossRefGoogle Scholar
  51. 51.
    Yoon H-J, Park K-M, Choi W-J, Choi S-H, Park J-Y, Kim J-J, Seok J-H. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Br Med J Psychiatry. 2013;13:240–51.Google Scholar
  52. 52.
    Smith HB, Fuchs DC, Pandharipande PP, Barr FE, Ely EW. Delirium: an emerging frontier in the management of critically ill children. Crit Care Clin. 2009;25:593–614.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Smith HAB, Brink E, Fuchs DC, Ely EW, Pandharipande PP. Pediatric delirium: monitoring and management in the pediatric intensive care unit. Pediatr Clin North Am. 2013;60:741–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Turkel SB, Jacobson JR, Munzig E, Tavaré CJ. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. J Child Adolesc Psychopharmacol. 2012;22:126–30.PubMedCrossRefGoogle Scholar
  55. 55.
    Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Design Dev Ther. 2013;7:657–67.CrossRefGoogle Scholar
  56. 56.
    Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chappie S, Phillips B, Adyemo T, Farewell D, Bisson JI. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res. 2010;69:485–90.PubMedCrossRefGoogle Scholar
  57. 57.
    Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine, and risperidone in delirium. J Psychosom Res. 2011;71:277–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Traube C, Witcher R, Mendez-Rico E, Silver G. Quetiapine as treatment for delirium in critically ill children: a case report. J Pediatr Intensive Care. 2013;2(3):121–6.Google Scholar
  59. 59.
    Meagher DJ. Delirium: optimizing management. Br Med J. 2001;322:144–9.CrossRefGoogle Scholar
  60. 60.
    Sloof V. Adverse events of haloperidol for the treatment of delirium in critically ill children. Crit Care Med. 2012;40(12 Suppl):1–338.Google Scholar
  61. 61.
    Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care. 2005;3:227–37.PubMedCrossRefGoogle Scholar
  62. 62.
    Michaud L, Bula C, Berney A, Camus V, Voellinger R, Stiefel F, Burnand B, Delirium Guidelines Development Group. Delirium: guidelines for general hospitals. J Psychosom Res. 2007;62:371–83.PubMedCrossRefGoogle Scholar
  63. 63.
    Alici-Evcimen Y, Breitbart W. An update on the use of antipsychotics in the treatment of delirium. Palliat Support Care. 2008;6:177–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Sonnier L, Barzman D. Pharmacologic management of acutely agitated pediatric patients. Pediatr Drugs. 2011;13(1):1–10.CrossRefGoogle Scholar
  65. 65.
    Schwartz CE. Delirium in hospitalized older patients. N Engl J Med. 1999;341:369–70.PubMedCrossRefGoogle Scholar
  66. 66.
    Sassano-Higgins S, Freudenberg N, Jacobson J, Turkel S. Olanzapine reduces delirium symptoms in the critically ill pediatric patient. J Pediatr Intensive Care. 2013;2:49–54.Google Scholar
  67. 67.
    Ben-Amor L. Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord. 2012;138:S22–50.PubMedCrossRefGoogle Scholar
  68. 68.
    Perrar KM, Golla H, Voltz R. Pharmacological treatment of delirium in palliative care patients. Der Schmerz. 2013;27:190–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Friedman JI, Soleimani L, McGonigle DP, Egol C, Silverstein JH. Pharmacological treatments of non-substance-withdrawal delirium: a systematic review of prospective trials. Am J Psychiatry. 2014;171(2):151–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50:8–15.PubMedCrossRefGoogle Scholar
  71. 71.
    Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012;43:906–13.PubMedCrossRefGoogle Scholar
  72. 72.
    De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Rev Endocrinol. 2012;8:114–26.CrossRefGoogle Scholar
  73. 73.
    Correll CU, Kratochvil CJ. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9–20.PubMedCrossRefGoogle Scholar
  74. 74.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–35.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Leonard CE, Freeman CP, Newcomb CW, Bilker WB, Kimmel SE, Strom BL, Hennessy S. Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiol. 2013;Suppl 10:1–9.Google Scholar
  76. 76.
    Washington NB, Brahm NC, Kissack J. Which psychotropic carry the greatest risk of QTc prolongation? Curr Psychiatr. 2012;11:36–9.Google Scholar
  77. 77.
    Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7263 treatment courses. J Clin Psychopharmacol. 2001;31:215–22.CrossRefGoogle Scholar
  78. 78.
    Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuro Psychopharm Biol Psychiatry. 2007;31:1255–60.CrossRefGoogle Scholar
  79. 79.
    Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Ripseridone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol. 1999;9:93–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Tabet N, Howard R. Pharmacological treatment for the prevention of delirium: review of current evidence. Int J Geriatr Psychiatry. 2009;24:1037–44.PubMedCrossRefGoogle Scholar
  81. 81.
    Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand. 2004;48:679–84.PubMedCrossRefGoogle Scholar
  82. 82.
    Bellaport J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012;108:572–80.CrossRefGoogle Scholar
  83. 83.
    Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo controlled trial. Int J Geriatr Psychiatry. 2011;26:687–94.PubMedCrossRefGoogle Scholar
  84. 84.
    Furuya M, Miyaoka T, Yasuda H, Yamashita S, Tanaka I, Otsuka S, Wake R, Horiguchi J. Marked improvement in delirium with ramelteon: five case reports. Psychogeriatrics. 2012;12:259–62.PubMedCrossRefGoogle Scholar
  85. 85.
    Kain ZN, MacLaren JE, Herrmann L, Mayes L, Rosenbaum A, Hata J, Lerman J. Preoperative melatonin and its effects on induction and emergence in children undergoing anesthesia and surgery. Anesthesiology. 2009;111:44–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71:1481–501.PubMedCrossRefGoogle Scholar
  87. 87.
    Shukry M, Clyde MC, Kalarickal PI, Ramadhyani U. Does dexmedetomidine prevent emergency delirium in children after sevoflurane-based general anesthesia? Pediatr Anesth. 2005;15:1098–104.CrossRefGoogle Scholar
  88. 88.
    Tobias JD, Gupta P, Naguib A. Dexmedetomidine: applications for the pediatric patient with congenital heart disease. Pediatr Cardiol. 2011;32:1075–87.PubMedCrossRefGoogle Scholar
  89. 89.
    Buck ML, Willson DF. Use of dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy. 2008;28(1):51–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Mason KP, Lerman J. Dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011;113(5):1129–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Pediatr Drugs. 2008;10(1):49–69.CrossRefGoogle Scholar
  92. 92.
    Honey BL, Benefield RJ, Miller JL, Johnson PN. α2-Receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother. 2009;43:1056–511.CrossRefGoogle Scholar
  93. 93.
    Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy. 2005;25(pt 2):8S–18S.PubMedCrossRefGoogle Scholar
  94. 94.
    Resnick M, Burton BT. Droperidol vs haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry. 1984;45:298–9.PubMedGoogle Scholar
  95. 95.
    Bourcher BA. Formulary decisions: then and now. Pharmacotherapy. 2010;6(Pt 2):35S–41S.CrossRefGoogle Scholar
  96. 96.
    Bostwick JM, Masterson BJ. Psychopharmacological treatment of delirium to restore mental capacity. Psychosomatics. 1998;39:112–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Shaw GK. Detoxification: the use of benzodiazepines. Alcohol Alcohol. 1995;30:765–70.PubMedGoogle Scholar
  98. 98.
    Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome: a focus on non-benzodiazepine GABA-ergic medications. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32:1106–17.CrossRefGoogle Scholar
  99. 99.
    Shaner R. Benzodiazepines in psychiatric emergency settings. Psychiatr Ann. 2000;30:268–75.CrossRefGoogle Scholar
  100. 100.
    Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, Bernard GR, Ely EW. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15:217–33.PubMedCrossRefGoogle Scholar
  102. 102.
    Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy. 1997;17(3):531–7.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Departments of Psychiatry and Pediatrics, Keck School of MedicineUniversity of Southern California, Children’s Hospital Los AngelesLos AngelesUSA

Personalised recommendations